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Abstract 
The aim of the study is to formulate a dosimetry index that can be used for Quality assessment of IMRT treatment 
plans of prostate site. To compare different radiotherapy plans different indices are utilized. The present study will 
attempt to combine all the indices into one unified quality index which can define the quality of a treatment plan 
and serve as a quality indicator of treatment plan developed among similar and different modalities. This quality 
index will incorporate homogeneity index, conformity index, dose gradient and coverage index resulting in a direct 
comparison to an ideal plan. We developed another index in this study related to sparing of organs i.e. UDI (OARs) 
that incorporate the doses of OARs to compare which plan is optimum in terms of target coverage and OARs 
sparing. In comparison to this UDI (OARs) another work was done to analyze the dosimetry of overall plan 
including target coverage and organ at risk sparing i.e. critical organ scoring index (COSI). To validate UDI 
(Target), UDI (OARs) and COSI, 22 patients were studied which were planned on IMRT. We also define the 
ranking of the plan according to their target coverage and organ sparing quantities as ‘Excellent’, ‘Good’, ‘Average’ 
or ‘Poor’ plan. UDI index for the target and organ at risk is found to be a useful tool to quantify a treatment plan 
quality when volumes with different dose prescription are treated. 
Keywords: Treatment planning system, Conformity index, Homogeneity index, Dose coverage, Dose gradient, 
Critical organs 
DOI: 10.7176/CMR/12-1-04 
Publication date: January 31st 2020 
 
1. Introduction  
Cancer is among the leading cause of deaths globally; including developing and developed countries. As 3rd world 
countries around the world become more socially affluent, cancer deaths are expected to rise significantly due to 
combination of lifestyle changes and rapidly degradation of  environmental factors [1]. According World Health 
Organization(WHO), developing countries account for nearly 72% of cancer death even though the average 
disease occurrence in these countries is lower in comparison to that of first world nations [1]. It is estimated that 
by 2030, the number of new cancer cases will mount to 21.7 million and 13 million patients will die owing to the 
growth and aging of the population. Prostate cancer is the third most common cancer in men and is expected to 
increase internationally [2]. Intensity modulated radiation therapy (IMRT) has been shown to be the preferred 
delivery method for prostate cancer [9]. For the evaluation of any treatment plan some tools are necessary to judge 
how accurate the plan meets the optimum objectives. The purpose of the treatment planning is to provide full dose 
to the target volume so it could have high conformity and homogeneity and to reduce the risk factors of organ at 
risks and limiting the doses of organ at risk below their tolerance limit.  
For the evaluation of treatment plan several indices could be used in separate as well as combined scoring 
system. Several indices are suggested for the evaluation of treatment plan which include homogeneity index 
conformity index dose coverage and dose gradient. Akpati et al. introduced the scoring system named UDI which 
incorporate all the indices mentioned above for the evaluation of target coverage [5]. Following UDI 
implementation this work developed the scoring system for organ at risk i.e. UDI (OAR) and Critical Organ 
Scoring Index (COSI) as well for the specific prostate IMRT. 
 
2. Materials and Methods  
2.1. Development of UDI for Target coverage 
Conformity index is defined as an extension of section-by-section dosimetric analysis and dose-volume histograms 
and can be defined as an absolute value resulting from the ratio between a fraction of the tumor volume and the 
volume covered with the certain isodose line [10]. Dose Homogeneity is defined as the ratio of the difference 
between the near-maximum and near-minimum absorbed dose to the median dose. Dose coverage index measures 
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how well the PTV is covered by the prescribed dose. It is defined as the ratio of PTV receiving the Prescribed dose. 
Whereas dose gradient Index describes the decrement of dose in high dose region and used to describe the 
relationship between the volume of tumor covered by the prescribed dose and the volume covered by the half of 
the prescribe dose. The ideal value of these indices defined above i.e. dose conformity, dose gradient and dose 
coverage is equal to 1 and dose homogeneity to score 0.0 for an ideal plan. 
Indices formulations, used in this study, are the following 
Conformity index      =  


  


, 
Homogeneity Index  =
%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Coverage Index  = 

 
Gradient Index =

%
 
Where TVRI is the PTV receiving the 95% of the prescribed dose, TV is the target volume of prostate, VRI is 
the volume receiving 95% of the prescribed dose, D2% is the volume receiving 2% of the prescribed dose (near-
maximum dose) and D98% is the volume receiving  98% of the prescribed dose (near-maximum dose) and D50% 
is the volume receiving 50% of the prescribed dose and V50% is the volume receiving 50% of the prescribed dose. 
The UDI (Target) formula based on mathematical logic is defined as; 
 UDI = (∑ (|1.0 −  | + 0.1!
"
#$%  X 10
4 
Where DIK are the indices i.e. dose coverage, dose conformity, dose homogeneity and dose gradient. Wk 
denotes the weighting factor that explain the overall importance of individual index. To prevent inflation of the 
UDI score the weightage factor should be equal to 1, i.e. W1 x W2 x W3 x W4 = 1 [5]. To analyze the individual 
index of UDI the indices whose ideal value is equal to 1.0 can be expressed in some generic function UDI (X) 
which can be defined as; 
                       UDI (X) = {| 1.0 – X| + 0.1} x 10 
Where X= {CI, DG and C} 
2.1.1. For the homogeneity index 
                      UDI (HI) = {|HI| + 0.1} x 10 
 
2.2. Development of UDI for OARs 
Another scoring index is developed for OARs i.e. UDI (OAR) to evaluate the best optimum plan in term of Organ 
at Risk. For this purpose, QUANTEC protocol for ca prostate were followed in order to analyze the organs with 
their respective tolerance doses as mentioned in the protocol (Table 1). 
                    UDI (OARs) = ∏ "#$% {∑
OARS(Planning!
2345(67898:8;!
"
#$% } 
Where VOARs (Planning) is the volume of OARs extracted from the DVH of dosimetric plan and VOARs(protocol) 
is the standard volume as per QUANTEC protocol. Wk denotes the weighting factor that explain the overall 
importance of individual organ). Different weightages were assigned to each organ with respect to their late 
toxicity effects and clinical importance. For example, Rectum is the most important organ in clinical aspect so 
greater value of weightage were assign to this organ as shown in Table 2 
 
2.3. Development of Critical Organ Scoring Index 
Another work was done simultaneously for the scoring of OARs to analyze the optimum plan in terms of OARs 
sparing and target coverage i.e. Critical Organ Scoring Index (COSI).  COSI is a measure of both, i.e. doses to 
target and critical organ at risk. To accomplish this, Histogram Analysis Radiotherapy (HART) software was 
followed to extract the formula which is used for the study. All calculation was done in Microsoft Excel. It can be 
expressed as:  
                                       COSI = [ 1 −  
∑ (234<!=>?@
AB
 ] 
Where V(OARs) is the fractional volume of ith organ at risk (OAR) receiving more or less than tolerance dose 
and (Wi) is the relative weight of fractional volume of each organ, and TCI is the total coverage index of the 
treatment plan. For an ideal dosimetry of plan, this index should be equal to = 1.0 
 
3. Results 
To evaluate the UDI scoring index for both target coverage and OARs, 22 patients of prostate cancer, planned with 
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IMRT Technique were randomly selected over a period of 2 years. 
For the evaluation of UDI(Target) and UDI (OAR), the mean and standard deviation were calculated for all 
dosimetry indices and for UDI as well. UDI values were collected and plotted to quantitatively compare and 
classify the results. Four classification groups were established based on the mean and standard deviation such that 
UDI scores greater than (µ+σ) were classified as poor, whereas scores from u to (µ+σ) classified as average, UDI 
scores from µ to (µ-σ) were classified good and score less than ((µ-σ) were excellent. Out of 55 treatment plans 
(20 patients), only 9 (5.85%) plans resulted “poor” plans and 11 (7.15%) plans were resulted as “excellent” plans. 
The most of the treatment plans were classified as “average” and “good” plans. The lowest value of UDI (Target) 
is 23, whereas the highest value of UDI (Target) is 63.97. Similar work was done for the evaluation of UDI (OAR) 
where, out of 20 cases, the minimum deviation of UDI is 0.20 and maximum deviation is 0.44. as shown in fig 1 
and 2. Figure 3 below show the UDI of target which explain the variation of different plans. The lowest score 
which represent the minimum deviation from an ideal plan (i.e. = 1) is 23 whereas the highest score represents the 
maximum deviation from an ideal plan is 63.91. The overall evaluation of each indices for an individual plan 
which include dose coverage (DCI), dose conformity (CI), dose homogeneity (HI) and dose gradient (DG) is 
shown in figure 4. Dose gradient is the most influential component for UDI b/c of relatively high magnitude of 
deviation from reference (ideal plan) values.  
 
4. DISCUSSION 
The dosimetry scoring method is a beneficial tool for the evaluation of quantitative and qualitative plan. It can also 
be used as a comparison tool for different plans of different modality 
 
4.1. UDI (OAR) comparison with UDI (Target) 
After evaluating all the data comparison was done between the UDI (OAR) and UDI (Target) just to observe the 
consistency and comparative result. It was observed that the case with excellent UDI (Target) score has the best 
UDI (OAR) value which means that UDI (Target) and UDI (OAR) are comparative to each other. Case with the 
worse target coverage has the worse sparing of OARs and case with good target coverage has the good sparing of 
OARs. As mentioned in table 2. 
To demonstrate the effect of UDI (Target) scoring method on dose distribution of worse to good plan, UDI 
score is associated, worse UDI score has worse dose distribution and good UDI score has good dose distribution 
as shown in figure 5. 
The dose distributions in case 5 show better dose conformity and dose homogeneity compared to the dose 
distribution in case 9 which is consistent with UDI score.  
Corresponding dose volume histogram (DVH) plots for both cases from worse to good for evaluating the 
dose coverage and organ at risk dose distribution. Evaluation of the DVH shows that both cases receive good dose 
coverage of PTV meeting the standard protocol i.e. (95% of the volume should receive 95% of the dose). But if 
we evaluate the doses of OARs (i.e. Rectum and bladder) it can be seen that in case 5 there is better dose 
distribution of OARs as compared to case 9, as shown in Figure 6 
 
4.2. UDI (Target) and UDI (OAR) Comparison with COSI 
Out of 55 cases, case 9 has worse UDI score which is 63.90 and case 5 has good UDI score which is 23.0 in term 
of target and OAR as well, both UDI (Target) and UDI (OAR) further compare with the COSI scoring system just 
to analyze the variation between each scoring system and comparative results, the worse value of COSI represent 
the worse UDI (OAR) and UDI (Target) and good value of COSI value represent the good value of UDI(OAR) 
and UDI  (Target) as shown in Table 3.  
 
5. CONCLUSION 
A scoring system developed for the evaluation of a dosimetry plan for IMRT prostate cancer. The proposed plan 
quality scoring system unifies four indices for the evaluation of target coverage into one simple equation which 
translate the overall quality of individual dosimetry plan. This work also proposed a similar method for creating a 
scoring system for organ at risk in which all the ratios of organs are covered into one equation that can be easily 
utilized for calculating a figure of merits and quantifies the overall quality of optimum dosimetry plan. UDI (OARs) 
and UDI (Target) were compared with Critical structure scoring index (COSI) and found to be in good agreement 
to validate the scoring of dosimetry of treatment plan. UDI index for the target and organ at risk is found to be a 
useful tool to quantify a treatment plan quality when volumes with different dose prescription are treated. Under 
this scoring system, for a collection of treatment plans, the quality of plans can be classified as ‘Excellent’ 
‘Average’ ‘Good’ and ‘Poor’ in term of target coverage and OARs. This proposed indexing system is not limited 
to only IMRT plans, but can be extended to compare the quality of plans that may be produced by other treatment 
techniques, like 3DCRT, IMRT, VMAT, SRS, etc. The proposed system can also be utilized to evaluate the plan 
quality of any other treatment sites by adjusting the OAR tolerance criteria following the clinical significance and 
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standard protocols. 
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Table 1: OARs Doses from QUANTEC protocol followed for the study. 
Organ End Point Dose Volume Parameter 
Rectum Grade ≥2/≥3 late toxicity 
Grade ≥2/≥3 late toxicity 
Grade ≥2/≥3 late toxicity 
Grade ≥2/≥3 late toxicity 
Grade ≥2/≥3 late toxicity 
V50 < 50% 
V60 < 35% 
V65 <25% 
V70 <20 
V75 <15% 
Bladder Grade ≥3 late toxicity V65 ≤ 50% 
V70 ≤ 35% 
V75 ≤ 25% 
Bowel Bag Severe erectile dysfunction Mean < 35 
Femoral Heads Necrosis Mean < 5 
 
Table 2: Organ at risk weightages with respect to their late toxicity effects and clinical importance. 
Organ at Risk Weightage 
Rectum 0.4 
Bladder 0.25 
Bowel Bag 0.05 
Femoral Heads 0.15 
 
Table 3: Illustration of UDI comparison between UDI (OARs) and UDI(T). Table explain the UDI target 
with worse score has the worse value of organ at risk sparing and the score with the minimum deviation of 
target coverage has the best score of Organ at Risk 
CASES UDI(Target) UDI(OARS) 
Case I            PI 40.27 0.44(Worse) 
  
  
            PII 60.64 
            PIII 63.91 
Case II           PI 34.18 0.30(Good) 
  
  
          PII 45.53 
          PIII 49.33 
Case III          PI 44.21   0.20(Excellent) 
          PII 23.00 
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Table 4: Illustration of scoring system comparison between UDI (OARs), UDI (Target) and COSI. Table 
explain the UDI target with worse score has the worse value of organ at risk sparing and COSI and the 
score with the minimum deviation of target coverage has the best score of Organ at Risk and COSI. 
CASES UDI (Target) UDI (OARS) COSI 
CaseI              PI 40.27 0.44(Worse) 
 
 
-5.58(Worse) 
 
 
               PII 60.64 
                PIII 63.91 
CaseII             PI 34.18 0.30(Good) 
 
 
-2.94(Good) 
 
 
               PII 45.53 
                PIII 49.33 
Case III            PI 44.21 0.20(Excellent) 
 
-1.56(Excellent) 
                 PII 23.00 
 
 
Figure 2:UDI (Target) ranking system based on mean and standard deviation. Ranked as ‘Excellent’ 
‘good’ ‘average’ and ‘poor’ 
 
 
Figure 3: UDI for organ at risk ranking system based on mean and standard deviation obtained for 20 
cases 
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Figure 4: histogram plot of unified dosimetry index for 55 IMRT treatment plans 
 
 
Figure 5: Histogram of UDI that contribute all four individual indices in term of equation, UDI(C), UDI(CI), 
UDI(HI), UDI(DG) which denotes coverage, dose homogeneity, dose gradient and, conformity index 
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Figure 6: Dose distribution of worse and good UDI score. Plot showing axial, coronal and sagittal view of 
dose distribution of cases with good UDI on top and worse UDI on bottom. The corresponding UDI score 
were 63.91 and 23.0, respectively 
 
 
Figure 7:Dose Volume Histogram (DVH) plots for PTV and OARs for case 5 on Left and case 9 on Right 
 
